Atenolol 50 mg film-coated tablets

… be used in patients with any of the following: • hypersensitivity to the active substance, or to any of the excipients listed in section 6.1 • cardiogenic shock • uncontrolled heart failure • sick sinus syndrome • second-or third-degree heart block • untreated phaeochromocytoma • metabolic acidosis • bradycardia (<45 bpm) • hypotension • severe peripheral arterial circulatory disturbances.

Atenolol, as with other beta-blockers, should not be used in patients with any of the following: • hypersensitivity to the active substance, or to any of the excipients listed in section 6.1 • cardiogenic shock • uncontrolled heart failure • sick sinus syndrome • second-or third-degree heart block • untreated phaeochromocytoma • metabolic acidosis • bradycardia (<45 bpm) …

… • cardiogenic shock • uncontrolled heart failure • sick sinus syndrome • second-or third-degree heart block • untreated phaeochromocytoma • metabolic acidosis • bradycardia (<45 bpm) • hypotension • severe peripheral arterial circulatory disturbances.

… to any of the excipients listed in section 6.1 • cardiogenic shock • uncontrolled heart failure • sick sinus syndrome • second-or third-degree heart block • untreated phaeochromocytoma • metabolic acidosis • bradycardia (<45 bpm) • hypotension • severe peripheral arterial circulatory disturbances.

Atenolol, as with other beta-blockers, should not be used in patients with any of the following: • hypersensitivity to the active substance, or to any of the excipients listed in section 6.1 • cardiogenic shock • uncontrolled heart failure • sick sinus syndrome • second-or third-degree heart block • untreated phaeochromocytoma • metabolic acidosis • bradycardia (<45 bpm) • hypotension • sev …

Atenolol, as with other beta-blockers, should not be used in patients with any of the following: • hypersensitivity to the active substance, or to any of the excipients listed in section 6.1 • cardiogenic shock • uncontrolled heart failure • sick sinus syndrome • second-or third-degree …

… ock • uncontrolled heart failure • sick sinus syndrome • second-or third-degree heart block • untreated phaeochromocytoma • metabolic acidosis • bradycardia (<45 bpm) • hypotension • severe peripheral arterial circulatory disturbances.

… given to patients with a history of anaphylactic reaction to such allergens. Such patients may be unresponsive to the usual doses of adrenaline (epinephrine) used to treat the allergic reactions. • May cause a hypersensitivity reaction including angioedema and urticaria. • Should be used with caution in the elderly, starting with a lesser dose (see Section 4.2). Since Atenolol is excreted via the kidneys, dosage should be reduced in patients with a creatinine clea …

… the elderly, starting with a lesser dose (see Section 4.2). Since Atenolol is excreted via the kidneys, dosage should be reduced in patients with a creatinine clearance of below 35 ml/min/1.73 m2. Although cardioselective (beta1) beta-blockers may have less effect on lung function than non-selective beta-blockers, as with all beta-blockers, these should be avoided in patients with reversible obstructive airways disease, unless there are compelling clinical reasons for their use. Where such reasons exist, Atenolol may be used with caution. Occasionally, some increase in airways resistance may occur in asthmatic patients however, and this may usually be reversed by commonly used dosage of bronchodilators such as salbutamol or isoprenaline. The label and patient information leaflet for this product state the following warning: “If you have ever had asthma or wheezing, you should not take this medicine unless you have discussed these symptoms with the prescribing doctor”. As with other beta-blockers, in patients with a phaeochromocytoma, an alpha-blocker should be given concomitantly. Information on sodium content This medicine contains less than 1 mmol (23 mg) o …

… aflet for this product state the following warning: “If you have ever had asthma or wheezing, you should not take this medicine unless you have discussed these symptoms with the prescribing doctor”. As with other beta-blockers, in patients with a phaeochromocytoma, an alpha-blocker should be given concomitantly. Information on sodium content This medicine contains less than 1 mmol (23 mg) of sodium per tablet, that is to say it is essentially 'sodium-free.'

… uch patients may be unresponsive to the usual doses of adrenaline (epinephrine) used to treat the allergic reactions. • May cause a hypersensitivity reaction including angioedema and urticaria. • Should be used with caution in the elderly, starting with a lesser dose (see Section 4.2). Since Atenolol is excreted via the kidneys, dosage should be reduced in patients with a creatinine clearance of below 35 ml/min/1.73 m2. Although cardioselective (beta1) beta-blockers may have less …

… In the rare instances when a treated patient develops symptoms which may be attributable to a slow heart rate and the pulse rate drops to less than 50–55 bpm at rest, the dose should be reduced. • May cause a more severe reaction to a variety of allergens when given to patients with a history of anaphylactic reaction to such allergens. Such patients may be unresponsive to the usual doses of adrenaline (epinephrine) used to treat the allergic reactions. • May cause a hypersensitivity reaction including angioedema and urticaria. • Should be used with caution in the elderly, starting with a lesser dose (see Section 4.2). Since Atenolol is excrete …

… the elderly, starting with a lesser dose (see Section 4.2). Since Atenolol is excreted via the kidneys, dosage should be reduced in patients with a creatinine clearance of below 35 ml/min/1.73 m2. Although cardioselective (beta1) beta-blockers may have less effect on lung function than non-selective beta-blockers, as with all beta-blockers, these should be avoided in patients with reversible obstructive airways disease, unless there are compelling clinical reasons for their use. Where such reasons exist, Atenolol may be used with caution. Occasionally, some increase in airways resistance may occur in asthmatic patients however, and this may usually be reversed by commonly used dosage of bronchodilators such as salbutamol or isoprenaline. The label and patient information leaflet for this product state the following warning: “If you have ever had asthma or wheezing, you should not take this medicine unless you have discussed these symptoms with the prescribing doctor”. As with other beta-blockers, in patients with a phaeochromocytoma, an alpha-blocker should be given concomitantly. Information on sodium content This medicine contains less than 1 mmol (23 mg) o …

… ts negative effect on conduction time, caution must be exercised if it is given to patients with first-degree heart block. • May mask the symptoms of hypoglycaemia, in particular, tachycardia. • May mask the signs of thyrotoxicosis. • Will reduce heart rate as a result of its pharmacological action. In the rare instances when a treated patient develops symptoms which may be attributable to a slow heart rate and the pulse rate …

… clonidine by beta-blocker therapy, the introduction of beta-blockers should be delayed for several days after clonidine administration has stopped. (See also prescribing information for clonidine.) Class I anti-arrhythmic drugs (e.g. disopyramide) and amiodarone may have a potentiating effect on atrial-conduction time and induce negative inotropic effect. Concomitant use of sympathomimetic agents, e.g. adrenaline (epinephrine), may counteract the effect of beta-blockers. Concomitant use with insulin and oral antidiabetic drugs may lead to the intens …

Caution should be exercised when Atenolol is administered during pregnancy or to a woman who is breast-feeding. Pregnancy Atenolol crosses the placental barrier and appears in the cord blood. No studies have been performed on the use of Atenolol in the first trimester and the possibility of foetal injury c …

… There is significant accumulation of Atenolol in breast milk. Neonates born to mothers who are receiving Atenolol at parturition or breast-feeding may be at risk of hypoglycaemia and bradycardia. Fertility There are no data available.

… ent of hypertension in the third trimester. Administration of Atenolol to pregnant women in the management of mild to moderate hypertension has been associated with intra-uterine growth retardation. The use of Atenolol in women who are, or may become, pregnant requires that the anticipated benefit be weighed against the possible risks, particularly in the first and second trimesters, since beta-blockers, in general, have been associated with a decrease in placental perfusion which may result in growth retardation, intra-uterine deaths, abortion, immature and premature deliveries. Breast-feeding There is significant accumulation of Atenolol in breast milk. Neonates born to mothers who are receiving Atenolol at parturition or breast-feeding may be at risk of hypoglycaemia …

… perfusion which may result in growth retardation, intra-uterine deaths, abortion, immature and premature deliveries. Breast-feeding There is significant accumulation of Atenolol in breast milk. Neonates born to mothers who are receiving Atenolol at parturition or breast-feeding may be at risk of hypoglycaemia and bradycardia. Fertility There are no data available.

Caution should be exercised when Atenolol is administered during pregnancy or to a woman who is breast-feeding. Pregnancy Atenolol crosses the placental barrier and appears in the cord blood. No studies have been performed on the use of Atenolol in the first trimester and the possibility of foetal injury c …

Not found in the sections read for this label. Not the same as the label being silent.

Not found in the sections read for this label. Not the same as the label being silent.

Not found in the sections read for this label. Not the same as the label being silent.

Not found in the sections read for this label. Not the same as the label being silent.

Not found in the sections read for this label. Not the same as the label being silent.

Not found in the sections read for this label. Not the same as the label being silent.

Not found in the sections read for this label. Not the same as the label being silent.

Not found in the sections read for this label. Not the same as the label being silent.

Not found in the sections read for this label. Not the same as the label being silent.

Not found in the sections read for this label. Not the same as the label being silent.

Not found in the sections read for this label. Not the same as the label being silent.